The U.S. Food & Drug Administration has approved ZEJULA™ (niraparib) for the maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following a complete or partial response to a platinum-based chemotherapy regimen. ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer.
